Clinical trial readout dates for Veracyte Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$4.5B
Cash & investments$200Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04
In progress, no date published
Phase 3NRG/RTOG 0521
Prostate cancer
date not published
Ongoing
Cash position
Veracyte Inc. reported $200M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $32M for that quarter.